Biodexa Shareholders Reverse Course, Approve 1-for-10,000 Reverse Split
BDRX sits 51% above its 52-week low of $1.02.
Summary
Biodexa Pharmaceuticals shareholders approved a 1-for-10,000 reverse stock split on July 29, 2026, reversing a prior rejection. Effective July 30, the move is essential for Nasdaq compliance and follows recent dilutive financings.
Key Events · Corporate Governance and Compliance · BDRX
-
Reverse Split Approved
Shareholders reversed their June 30, 2026 rejection and approved a 1-for-10,000 reverse stock split. Effective July 30, the move reduces outstanding ordinary shares to 51,453,281, equivalent to 1,029,063 ADSs.
-
ADS Ratio Adjustment
The ADS ratio shifts from 1 ADS per 500,000 ordinary shares to 1 ADS per 50 ordinary shares, with no change in proportional ownership.
-
Share Issuance Authority Granted
Directors were authorized to allot ordinary shares on a non-pre-emptive basis, adding potential future dilution.
-
Nasdaq Compliance at Stake
The reverse split is critical for maintaining Nasdaq listing requirements, following a series of highly dilutive offerings in July 2026.
Analysis · BDRX · Life Sciences
In a sharp reversal from their June 30, 2026 rejection, Biodexa shareholders approved a 1-for-10,000 reverse stock split on July 29. The split takes effect July 30, slashing outstanding ordinary shares to 51.5 million and resetting the ADS ratio to 1:50—without altering proportional ownership. This approval is pivotal for the company's efforts to maintain its Nasdaq listing and advance its financing strategy, especially after a string of highly dilutive offerings. Adding to the picture, the board also secured authority to issue shares on a non-pre-emptive basis, which introduces potential future dilution risk.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 49% of the 206 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.93%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $1.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.7B. The 52-week trading range was $1.02 to $59.40. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.